Recurrent and De Novo Autoimmune Liver Diseases

Flavia Mendes; Claudia A. Couto; Cynthia Levy

doi:10.1016/j.cld.2011.08.008

Recurrent and De Novo Autoimmune Liver Diseases

Flavia Mendes, Claudia A. Couto, Cynthia Levy

Medicine

Research output: Contribution to journal › Review article › peer-review

23 Scopus citations

Abstract

Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH) each account for approximately 5% of liver transplants per year performed in the United States and Europe. Even though outcomes are excellent, with reported 5-year patient and graft survival exceeding 90% and 80%, 80% and 75%, 72% and 65% for PBC, PSC, and AIH, respectively, the issue of recurrent autoimmune liver disease after orthotopic liver transplantation is increasingly recognized as a cause of graft dysfunction, death, and need for retransplantation. This article reviews diagnostic criteria, epidemiology, risk factors, and outcomes of recurrent PBC, PSC, and AIH after liver transplantation.

Original language	English (US)
Pages (from-to)	859-878
Number of pages	20
Journal	Clinics in liver disease
Volume	15
Issue number	4
DOIs	https://doi.org/10.1016/j.cld.2011.08.008
State	Published - Nov 1 2011

Keywords

Autoimmune hepatitis
Liver transplantation
Primary biliary cirrhosis
Primary sclerosing cholangitis
Recurrence

ASJC Scopus subject areas

Hepatology

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1016/j.cld.2011.08.008

Fingerprint Dive into the research topics of 'Recurrent and De Novo Autoimmune Liver Diseases'. Together they form a unique fingerprint.

Cite this

@article{d71dd1d85181432ea2f112ec76ab32a5,

title = "Recurrent and De Novo Autoimmune Liver Diseases",

abstract = "Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH) each account for approximately 5% of liver transplants per year performed in the United States and Europe. Even though outcomes are excellent, with reported 5-year patient and graft survival exceeding 90% and 80%, 80% and 75%, 72% and 65% for PBC, PSC, and AIH, respectively, the issue of recurrent autoimmune liver disease after orthotopic liver transplantation is increasingly recognized as a cause of graft dysfunction, death, and need for retransplantation. This article reviews diagnostic criteria, epidemiology, risk factors, and outcomes of recurrent PBC, PSC, and AIH after liver transplantation.",

keywords = "Autoimmune hepatitis, Liver transplantation, Primary biliary cirrhosis, Primary sclerosing cholangitis, Recurrence",

author = "Flavia Mendes and Couto, {Claudia A.} and Cynthia Levy",

year = "2011",

month = nov,

day = "1",

doi = "10.1016/j.cld.2011.08.008",

language = "English (US)",

volume = "15",

pages = "859--878",

journal = "Clinics in Liver Disease",

issn = "1089-3261",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - Recurrent and De Novo Autoimmune Liver Diseases

AU - Mendes, Flavia

AU - Couto, Claudia A.

AU - Levy, Cynthia

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH) each account for approximately 5% of liver transplants per year performed in the United States and Europe. Even though outcomes are excellent, with reported 5-year patient and graft survival exceeding 90% and 80%, 80% and 75%, 72% and 65% for PBC, PSC, and AIH, respectively, the issue of recurrent autoimmune liver disease after orthotopic liver transplantation is increasingly recognized as a cause of graft dysfunction, death, and need for retransplantation. This article reviews diagnostic criteria, epidemiology, risk factors, and outcomes of recurrent PBC, PSC, and AIH after liver transplantation.

AB - Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and autoimmune hepatitis (AIH) each account for approximately 5% of liver transplants per year performed in the United States and Europe. Even though outcomes are excellent, with reported 5-year patient and graft survival exceeding 90% and 80%, 80% and 75%, 72% and 65% for PBC, PSC, and AIH, respectively, the issue of recurrent autoimmune liver disease after orthotopic liver transplantation is increasingly recognized as a cause of graft dysfunction, death, and need for retransplantation. This article reviews diagnostic criteria, epidemiology, risk factors, and outcomes of recurrent PBC, PSC, and AIH after liver transplantation.

KW - Autoimmune hepatitis

KW - Liver transplantation

KW - Primary biliary cirrhosis

KW - Primary sclerosing cholangitis

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=80054962713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054962713&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2011.08.008

DO - 10.1016/j.cld.2011.08.008

M3 - Review article

C2 - 22032533

AN - SCOPUS:80054962713

VL - 15

SP - 859

EP - 878

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 4

ER -

Recurrent and De Novo Autoimmune Liver Diseases

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this